Maravai LifeSciences Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed life sciences operating company with Class A common stock. Form 8-K reports furnish quarterly and annual financial results, including revenue, net loss, adjusted EBITDA and business updates for the TriLink nucleic acid synthesis and Cygnus biologics safety testing operations.
The company’s proxy materials describe annual meeting matters, director elections, independent auditor ratification, executive compensation votes and board governance. Other current reports record leadership succession, board-size and committee changes, equity-award treatment, and restructuring actions classified as exit or disposal activities, including related cost disclosures and risk language.
Maravai LifeSciences Holdings, Inc. ownership update: 12 West Capital Management and Joel Ramin report beneficial ownership of 7,260,195 shares of Class A Common Stock, representing 4.9% of the class. The percent is calculated using 146,383,162 shares outstanding as of February 19, 2026.
The statement, filed as an amendment, attributes shared voting and shared dispositive power over the reported shares to the 12 West Funds and identifies Mr. Ramin as the managing member of the reporting manager. Signatures are dated May 15, 2026.
Maravai LifeSciences Holdings, Inc. group filing amends beneficial ownership disclosure to report 13,488,799 shares of Class A common stock, representing 9.21% of the class. The filing lists the reporting group members and per-member sole voting/dispositive holdings, including Stuart Feldman with 10,337,680 shares (7.06%) and Hudson View Holdings LLC with 7,337,680 shares (5.01%). The filing is a joint Schedule 13G/A amendment signed by the group representatives on 05/14/2026.
Maravai LifeSciences Holdings, Inc. Schedule 13G filing reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclosed shared voting and dispositive power over 7,228,864 shares of Class A Common Stock, representing 4.9% of the class. The filing states they acquired beneficial ownership of more than 5% on May 6, 2026 and ceased to exceed 5% by the filing date. A Joint Filing Agreement dated May 11, 2026 is attached.
Maravai LifeSciences reported stronger results for the three months ended March 31, 2026. Revenue rose to $65.8 million from $46.9 million, driven mainly by its TriLink segment, which increased to $47.5 million, while Cygnus revenue was stable at $18.4 million.
Gross margin improved sharply to 51.2% from 16.5% as cost of revenue fell and product mix shifted, helped by $14.3 million of high-volume CleanCap® COVID-19 vaccine orders. Net loss narrowed to $6.4 million from $52.9 million, and Adjusted EBITDA turned to a $20.3 million profit from a $10.5 million loss.
Operating expenses declined significantly due to the 2025 Corporate Realignment Plan, which reduced selling, general and administrative and research and development spending but added $2.9 million of restructuring costs. The company used cash to voluntarily prepay $50.0 million of its Term Loan, lowering long‑term debt to $242.9 million while ending the quarter with $165.9 million in cash and cash equivalents.
Maravai LifeSciences Holdings, Inc. reported much stronger results for the first quarter ended March 31, 2026. Revenue rose to $65.8 million, up 40.5% from the prior-year period, driven mainly by TriLink, which delivered $47.5 million of revenue, including $14.3 million from high-volume CleanCap orders for commercial COVID-19 vaccine programs.
The company posted a net loss of $6.4 million, a sharp improvement from a $52.9 million loss a year earlier, as gross profit expanded and operating expenses declined without the prior goodwill impairment. Adjusted EBITDA turned positive to $20.3 million from a loss of $10.5 million, and free cash flow improved to $4.2 million from negative $13.9 million, indicating better cash generation.
On the back of this performance, Maravai raised its full-year 2026 guidance, now expecting revenue between $205.0 million and $215.0 million and Adjusted EBITDA between $30.0 million and $32.0 million, compared with prior ranges of $200.0–$210.0 million and $18.0–$20.0 million. Management highlighted improving demand in its core TriLink base, non-COVID business and ongoing cost and efficiency initiatives.
Maravai LifeSciences Holdings, Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on May 26, 2026, at 2:30 p.m. Pacific Time. Holders of Class A and Class B common stock as of March 27, 2026 can vote online, by phone or by mail.
Shareholders will elect three Class III directors (Bernd Brust, Gregory T. Lucier and Luke Marker) to terms ending at the 2029 meeting, ratify Deloitte & Touche LLP as auditor for 2026, and cast an advisory say‑on‑pay vote on named executive officer compensation. The proxy also details board structure, committee responsibilities, GTCR’s director nomination rights, and the company’s pay‑for‑performance compensation philosophy, including 2025 leadership transitions and base salaries for key executives.
MARAVAI LIFESCIENCES HOLDINGS, INC. officer Christine Dolan reported a routine tax-withholding transaction related to restricted stock units. On March 16, 2026, 28,661 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations on vesting awards. After this non-market disposition, she directly holds 420,312 shares of Class A common stock.
Maravai Lifesciences Holdings General Counsel Kurt Oreshack reported a routine tax-withholding transaction in company stock. On the vesting of restricted stock units, 39,976 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations. After this non-market disposition, he directly holds 384,991 shares of Maravai stock.
Maravai LifeSciences Holdings, Inc. reports its 2025 business overview, risk profile and strategy as a specialized life sciences supplier to drug, vaccine and diagnostics developers. The company operates through two segments: TriLink, focused on mRNA and nucleic acids, generated 64% of 2025 revenue, while Cygnus, focused on biologics safety testing, contributed 36%.
Key products include CleanCap® mRNA capping, ModTail™ poly(A) technology, custom mRNA and GMP manufacturing, and Cygnus host cell protein ELISA and MockV® viral clearance tools, backed by an extensive global patent portfolio. As of December 31, 2025, Maravai had 435 full-time employees and an aggregate non‑affiliate market value of about $300.0 million. High-volume CleanCap® sales for commercial vaccine programs fell to about 0.0% of 2025 revenue after representing 25.4% in 2024 and 21.0% in 2023, highlighting demand volatility.
In 2025 the company renamed its segments to align with its TriLink and Cygnus brands, adopted AI- and machine-learning–based design tools, and launched a Corporate Realignment Plan that includes cutting roughly 25% of the workforce and reducing facilities to lower costs and refocus on long-term growth.